摘要:
An object of the present invention is to provide a therapeutic agent for allergy which realizes enhancement of therapeutic efficacy and improvement in side effects such as anaphylaxis in a method for treating allergy by allergen administration (hyposensitization therapy).That is, the present invention provides the therapeutic agent for allergy comprising a liposome having on its surface an oligosaccharide capable of binding to a lectin derived from an antigen presenting cell and composed of 2 to 11 sugar residues, wherein an allergen is encapsulated in said liposome.
摘要:
A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided. That is, the present invention provides the immunostimulatory oligonucleotide composed of a base sequence represented by a formula: 5′-(G)MPXCGYQ(G)N-3′ (SEQ ID NO: 118) (X and Y are mutually independent and represent an arbitrary sequence which has a length of 0 to 10 nucleotides and does not contain 4 or more consecutive G residues, and a length of X+Y is 6 to 20 nucleotides; XCGY contains a palindrome sequence having a length of at least 8 nucleotides and has a length of 8 to 22 nucleotides; P and Q are mutually independent and represent one nucleotide other than G; M represents an integer of 6 to 10 and N represents an integer of 0 to 3) wherein a full length thereof is 16 to 37 nucleotides (except for an oligonucleotide composed of a base sequence represented by SEQ ID NO:5), the pharmaceutical application thereof.
摘要翻译:提供了IFN诱导活性增强并且减少炎性细胞因子诱导活性的新型免疫刺激性寡核苷酸,并且提供了含有该诱导活性的药物及其应用。 也就是说,本发明提供了由以下通式表示的碱基序列组成的免疫刺激性寡核苷酸:5' - (G)MPXCGYQ(G)N-3'(SEQ ID NO:118)(X和Y相互独立, 长度为0〜10个核苷酸且不含4个以上连续G残基的任意序列,X + Y的长度为6〜20个核苷酸; XCGY含有长度至少为8个核苷酸的回文序列, 长度为8〜22个核苷酸; P和Q相互独立,表示除G以外的一个核苷酸; M表示6〜10的整数,N表示0〜3的整数),其全长为16〜37 核苷酸(除了由SEQ ID NO:5表示的碱基序列组成的寡核苷酸),其药学应用。
摘要:
A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided. That is, the present invention provides the immunostimulatory oligonucleotide composed of a base sequence represented by a formula: 5′-(G)MPXCGYQ(G)N-3′ (X and Y are mutually independent and represent an arbitrary sequence which has a length of 0 to 10 nucleotides and does not contain 4 or more consecutive G residues, and a length of X+Y is 6 to 20 nucleotides; XCGY contains a palindrome sequence having a length of at least 8 nucleotides and has a length of 8 to 22 nucleotides; P and Q are mutually independent and represent one nucleotide other than G; M represents an integer of 6 to 10 and N represents an integer of 0 to 3) wherein a full length thereof is 16 to 37 nucleotides (except for an oligonucleotide composed of a basesequence represented by SEQ ID NO:5), the pharmaceutical application thereof.